tbuckley/cabot-search huggingface dataset:
BENIGN ESSENTIAL HYPERTENSION: FOLLOW-UP OF 100 PATIENTS UNDER OBSERVATION FOR FROM 18 TO 34 YEARS
Authors: A M BURGEES
Journal: Annals of Internal Medicine (1955)

Article1 October 1955BENIGN ESSENTIAL HYPERTENSION: FOLLOW-UP OF 100 PATIENTS UNDER OBSERVATION FOR FROM 18 TO 34 YEARSALEX. M. BURGESS, M.D., F.A.C.P.ALEX. M. BURGESS, M.D., F.A.C.P.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-43-4-740 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptThis is a report on the condition of 100 patients seen in private practice between the years 1920 and 1936. All had systolic pressures of at least 180 mm. Hg or diastolic pressures of 100 mm. Hg or higher when first observed, and had survived for at least eight years. These were the first hundred individuals seen in the practice of the writer to whom these criteria were applicable. The group was reported in 1946,1 and the present communication summarizes their condition in the fall of 1954.A number of studies of prognosis in patients with essential hypertension have been...Bibliography1. Burgess AM: Excessive hypertension of long duration, New England J. Med. 239: 75 (July 15) 1948. CrossrefMedlineGoogle Scholar2. O'HareHolden JPRB: Longevity in benign hypertension, J. A. M. A. 149: 1453 (Aug. 16) 1952. CrossrefMedlineGoogle Scholar3. GriepBarryHallHoobler AHGRWCSW: Prognosis in arterial hypertension, Am. J. M. Sc. 221: 239 (Mar.) 1951. CrossrefMedlineGoogle Scholar4. HammarstromBechgaard SP: Prognosis in arterial hypertension, Am. J. Med. 8: 53 (Jan.) 1950. CrossrefMedlineGoogle Scholar5. DublinLotka LIAJ: Length of life, a study of the life table, 1936, Ronald Press Co., New York. Google Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Providence, Rhode Island*Received for publication May 17, 1955. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byHypertensionRecent advances in hypertensionAntihypertensive AgentsThe natural history of hypertensionHypertonieHypertonie 1 October 1955Volume 43, Issue 4Page: 740-744KeywordsBlood pressureFallsHypertensionLesionsSystolic pressure ePublished: 1 December 2008 Issue Published: 1 October 1955 PDF downloadLoading ...
Handbuch der Kinderheilkunde.
Authors: Heinz F. Eichenwald
Journal: JAMA (1924)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Oral aprepitant in the therapy of refractory pruritus in erythrodermic cutaneous T-cell lymphoma
Authors: N. Booken, M. Heck, J.P. Nicolay, C.D. Klemke, S. Goerdt, J. Utikal
Journal: British Journal of Dermatology (2010)

Journal Article Oral aprepitant in the therapy of refractory pruritus in erythrodermic cutaneous T‐cell lymphoma Get access N. Booken, N. Booken Department of Dermatology, Venereology and Allergology, University Medical Centre Mannheim, Ruprecht‐Karl‐University of Heidelberg, 68135 Mannheim, Germany E‐mail: Nina.Booken@umm.de Search for other works by this author on: Oxford Academic Google Scholar M. Heck, M. Heck Department of Dermatology, Venereology and Allergology, University Medical Centre Mannheim, Ruprecht‐Karl‐University of Heidelberg, 68135 Mannheim, Germany E‐mail: Nina.Booken@umm.de Search for other works by this author on: Oxford Academic Google Scholar J.P. Nicolay, J.P. Nicolay Department of Dermatology, Venereology and Allergology, University Medical Centre Mannheim, Ruprecht‐Karl‐University of Heidelberg, 68135 Mannheim, Germany E‐mail: Nina.Booken@umm.de Search for other works by this author on: Oxford Academic Google Scholar C.D. Klemke, C.D. Klemke Department of Dermatology, Venereology and Allergology, University Medical Centre Mannheim, Ruprecht‐Karl‐University of Heidelberg, 68135 Mannheim, Germany E‐mail: Nina.Booken@umm.de Search for other works by this author on: Oxford Academic Google Scholar S. Goerdt, S. Goerdt Department of Dermatology, Venereology and Allergology, University Medical Centre Mannheim, Ruprecht‐Karl‐University of Heidelberg, 68135 Mannheim, Germany E‐mail: Nina.Booken@umm.de Search for other works by this author on: Oxford Academic Google Scholar J. Utikal J. Utikal Department of Dermatology, Venereology and Allergology, University Medical Centre Mannheim, Ruprecht‐Karl‐University of Heidelberg, 68135 Mannheim, Germany E‐mail: Nina.Booken@umm.de Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 164, Issue 3, 1 March 2011, Pages 665–667, https://doi.org/10.1111/j.1365-2133.2010.10108.x Published: 01 March 2011
In early septic shock, early goal-directed therapy did not reduce 90-day mortality
Authors: Dharmvir S. Jaswal, Peter Q. Eichacker
Journal: Annals of Internal Medicine (2015)

ACP Journal Club18 August 2015In early septic shock, early goal-directed therapy did not reduce 90-day mortalityDharmvir S. Jaswal, MD, Peter Q. Eichacker, MDDharmvir S. Jaswal, MDCritical Care Medicine Department, Clinical Center, National Institutes of Health, Bethesda, Maryland, USA (D.S.J., P.Q.E.)Search for more papers by this author, Peter Q. Eichacker, MDCritical Care Medicine Department, Clinical Center, National Institutes of Health, Bethesda, Maryland, USA (D.S.J., P.Q.E.)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/ACPJC-2015-163-4-010 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Source CitationMouncey PR, Osborn TM, Power GS, et al; ProMISe Trial Investigators. Trial of early, goal-directed resuscitation for septic shock. N Engl J Med. 2015;372:1301-11. https://pubmed.ncbi.nlm.nih.gov/25776532Clinical Impact RatingsEmergency Med: Hospitalists: Critical Care: References1. Rivers E, Nguyen B, Havstad S, et al; Early Goal-Directed Therapy Collaborative Group. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med. 2001;345:1368-77. [PMID: 11794169] Google Scholar2. Levy MM, Dellinger RP, Townsend SR, et al; Surviving Sepsis Campaign. The Surviving Sepsis Campaign: results of an international guideline-based performance improvement program targeting severe sepsis. Crit Care Med. 2010;38:367-74. [PMID: 20035219] Google Scholar3. Huang DT, Angus DC, Barnato A, et al; ProCESS/ARISE/ProMISe Methodology Writing Committee. Harmonizing international trials of early goal-directed resuscitation for severe sepsis and septic shock: methodology of ProCESS, ARISE, and ProMISe. Intensive Care Med. 2013;39:1760-75. [PMID: 23958738] Google Scholar4. Bellomo R, Warrillow SJ, Reade MC. Why we should be wary of single-center trials. Crit Care Med. 2009;37:3114-9. [PMID: 19789447] Google Scholar Author, Article, and Disclosure InformationAffiliations: Critical Care Medicine Department, Clinical Center, National Institutes of Health, Bethesda, Maryland, USA (D.S.J., P.Q.E.)This article was published at Annals.org on 4 August 2015. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 18 August 2015Volume 163, Issue 4Page: JC10KeywordsEmergency departmentIntensive care unitsLength of stayMortalityResearch assessmentResuscitationSepsisSequential organ failure assessmentShock ePublished: 18 August 2015 Issue Published: 18 August 2015 Copyright & PermissionsCopyright © 2015 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
406. Determination of the Most Efficient Vector System for Gene Transduction into Dendritic Cells (DC)
Authors: Eigo Satoh, Hua Yan, Xiao-Kang Li, Wataru Sugiura, Naoki Yamamoto, Kenichi Teramoto, Shigeki Arii, Hiromitsu Kimura
Journal: Molecular Therapy (2004)

Background: It has been well established that the specialized antigen presenting cells (APC), dendritic cells (DC), play a pivotal role in initiating a primary immune response. Although it has been reported that several vector systems including Adenoviral vector, HVJ liposome, inactivated HVJ vector, and electroporation-based plasmid vector systems, are able to transduce the genes into the DC in mouse and human, this is not the case with rat DC. In addition to this, it appears that the reported studies were not always employing highly purified DC and, to our best knowledge, there has been no direct evidence to support the view that currently used-vector systems are able to effectively transduce the gene into DC. Inasmuch as most, if not all, DC or DC-related gene-transfer studies are performed by employing heterogeneous cell populations, it is important to determine whether and to what extent each vector system is able to transduce the gene into DC.
Histochemical Observations on Enzymatic Processes of Experimental Carcinogenesis in Hamster Cheek Pouch
Authors: Masahiko Mori, Tetuhiko Miyaji, Iwao Murata, Hiroshi Nagasuna
Journal: Cancer Research (1962)

Histochemical observations were made of hydrolytic and dehydrogenases during experimental carcinogenesis induced by 9,10-dimethyl-1,2-benzanthracene in a hamster cheek pouch.

Alkaline phosphatase activity was found on the surface of the neoplastic epithelium with heavy inflammation, and nonspecific esterase and β-glucuronidase had a moderate to high activity in the germinal layer of the neoplastic epithelium. Succinic dehydrogenase activity was shown in the germinal layer, but malic and lactic dehydrogenase reacted more intensely than did succinic dehydrogenase. The hornified layer of neoplasms was devoid of these three dehydrogenases. However, acid phosphatase activity was strikingly present. Aminopeptidase and polysaccharide in neoplasms showed little or no reaction.

Little or no activity of these enzymes was present in the stromal elements of tumors.
Anti-tumor necrosis factor-alpha treatment reduces allergic responses in an allergic rhinitis mouse model
Authors: J.-H. Mo, E.-K. Kang, S.-H. Quan, C.-S. Rhee, C. H. Lee, D.-Y. Kim
Journal: Allergy (2010)

To cite this article: Mo J-H, Kang E-K, Quan S-H, Rhee C-S, Lee CH, Kim D-Y. Anti-tumor necrosis factor-alpha treatment reduces allergic responses in an allergic rhinitis mouse model. Allergy 2011; 66: 279–286. Abstract Background: Tumor necrosis factor (TNF)-α is a principal mediator of the acute inflammatory response, including allergic rhinitis. TNF-α inhibitors are widely used for the treatment of inflammatory conditions such as rheumatoid arthritis and inflammatory bowel diseases; however, the effects of TNF-α inhibitors on allergic rhinitis are not well established. We aimed to investigate the effects of infliximab, a TNF-α inhibitor, on allergic rhinitis in a mouse model. Methods: BALB/c mice were sensitized with ovalbumin (OVA) and alum, and challenged intranasally with OVA. The TNF-α inhibitor, infliximab was administered intraperitoneally, and multiple parameters of allergic responses were evaluated to determine the effects of infliximab. Results: Infliximab reduced allergic symptoms and eosinophilic infiltration into the nasal mucosa. It also suppressed total and OVA-specific IgE levels, and inhibited local Th2 cytokine transcription in the nasal mucosa and systemic Th2 cytokine production by splenocytes. Furthermore, the expression of E-selectin, neither intercellular adhesion molecule 1 (ICAM-1) nor vascular cell adhesion molecule 1 (VCAM-1), in the nasal mucosa was suppressed in the infliximab-treated group when compared to the nontreated group. Conclusion: This study shows that the TNF-α inhibitor infliximab induces anti-allergic effects by decreasing local and systemic Th2 cytokine (IL-4) production, total and OVA-specific IgE levels, adhesion molecule (E-selectin) expression, and eosinophil infiltration into the nasal mucosa in an allergic rhinitis model. Therefore, infliximab should be considered as a potential agent in treating allergic rhinitis.
Visualization of the foci of recombinant AAV replication and their relationship with cellular proteins involved in the recognition and repair of double-stranded DNA breaks
Authors: Tiziana Cervelli, Lorena Zentilin, Alessandro Marcello, Mauro Giacca
Journal: Molecular Therapy (2004)

Several properties of AAV are very attractive for human gene therapy; however, many aspects of its life cycle and, in particular, the molecular determinants of cellular permissivity to these vectors, are still largely unexplored. In cultured cells, increased efficiency of wt AAV or rAAV trasduction can be obtained by treating cells with agents that affect genomic DNA integrity or metabolism. This effect correlates with an improved conversion of the vector genome into dsDNA. This observation led to the possibility that permissivity for AAV trasduction could be linked to the induction of DNA damage checkpoints or of DNA repair mechanisms that mediate replication of ss DNA genomes. A few years ago, we have indeed observed that proteins involved in dsDNA break (DSB) repair bind to the incoming rAAV genomes and regulate vector replication.
MALARIA COMPLICATED BY PNEUMONIA; TREATMENT WITH SULFADIAZINE AND ATABRINE
Authors: Z. Taylor Bercovitz
Journal: Annals of Internal Medicine (1945)

Case Reports1 July 1945MALARIA COMPLICATED BY PNEUMONIA; TREATMENT WITH SULFADIAZINE AND ATABRINEZ. TAYLOR BERCOVITZ, F.A.C.P.Z. TAYLOR BERCOVITZ, F.A.C.P.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-23-1-79 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptThe purpose of this paper is to report the case of a patient suffering with P. falciparum malaria complicated by pneumonia and successfully treated with both atabrine and sulfadiazine. The clinical picture of the onset of pneumonia confused the picture by suggesting a relapse of the malaria. The diagnosis was cleared up by physical examination.CASE REPORTE. D. S., a white male, 53 years old, was brought to the attention of the writer because during what was presumably a relapse of malaria he failed to respond to the administration of quinine. The patient was an engineer who two weeks...Bibliography1. HARNEDCOLE BKVV: A therapeutic incompatibility between sulfapyridine and quinine, Jr. Pharmacol. and Exper. Therap., 1942, lxxiv, 42-51. Google Scholar2. Personal communication from the Standard Oil Company. Google Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: M.C. A.U.S.*Received for publication February 19, 1944.From the Department of Medicine, New York Post-Graduate Medical School and Hospital. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 July 1945Volume 23, Issue 1Page: 79-82KeywordsEngineersHospital medicineMalariaPneumoniaQuinine ePublished: 1 December 2008 Issue Published: 1 July 1945 PDF downloadLoading ...
Abstract 18502: Defects of Myocardial Mitochondrial Function in Patients With End-stage Heart Failure Are Associated With Reduced EndonucleaseG
Authors: Vojtech Melenovsky, Tomas Mracek, Jan Benes, Hana Nuskova, Drahota Zdenek, Jana Kovalcikova, Jan Pirk, Rudolf Poledne, Josef Houstek
Journal: Circulation (2014)

Introduction: The role of mitochondrial function impairment in heart failure (HF) is poorly understood. Endonuclease G (EndoG) is nuclear-encoded, mitochondria-localised nuclease, experimentally implicated in apoptosis, mtDNA function, ROS production and cardiac mass regulation, but its relevance to human HF has never been addressed. Hypothesis: Mitochondrial function is reduced in advanced human HF and is paralleled by reduction in EndoG. Methods: LV free-wall samples was obtained from 62 consecutive patients undergoing heart transplantation (HF group; LVEF 23±9%, age 51±12y, 80% males, 31% diabetes-DM, 41%CAD) and from 20 HF-free organ donors (CON group; LVEF 55±12%, age 41±15y, 55% males, 12% DM). Results: Compared to CON, HF patients had reduced mtDNA content (-24%, p<0.001). HF patients displayed reduced activity of citrate synthase (CS: -26%, p<0.001) and of OXPHOS enzymes NCCR (-24%,p<0.01), SCCR (-40%, p<0.001) and cytocrome-c oxidase (COX: -38%, p<0.001). Oxygraphy confirmed the reduction in COX ...
Abstract P228: Cardiovascular Risk Profiles and the 10-Year Risk of Atherosclerotic Cardiovascular Disease in HIV Infected Adult African American Females Using ACC/AHA 2013 Pooled Cohort Risk Equation (Findings from a Minority Healthcare University Institute in Washington DC, USA)
Authors: Mohamed Jalloh, Tammie Blair, Kwame Tuffuor, Johanna Tesfay, Richa Mandlewala, Darin Roberts, Celia J Maxwell, Muhammad Amer
Journal: Circulation (2015)

Back ground: Data on the patterns of cardiovascular disease (CVD) risk factors in HIV-infected African American Females (AAF) is limited due to their under-representation in epidemiological studies. We examined patterns of CVD risk factors and estimated 10-year primary risk of Atherosclerotic Cardiovascular Disease (ASCVD) in HIV-infected [on highly active antiretroviral therapy (HAART)], and compared with HIV-uninfected adult AAF seeking routine medical care in a minority healthcare institute in Washington DC, USA.

Methods: The study cohort comprised of HIV-infected and age-matched HIV-uninfected adult (age > 20 years) AAF seeking routine health and HIV care (3-6 month intervals) at a large minority healthcare university institute. Data on demographic and HIV characteristics as well as cardiovascular risk profile was compared in participants with a minimum of five clinic visits since registration. Race adjusted, pooled cohort equation was used to estimate and compare 10-year primary risk of ASCVD in HIV-infected females (age ≥ 40 to 79 years), free of pre-existing CVD at baseline to their age-matched controls.

Results: The mean (SD) age, systolic blood pressure, and BMI of 325 (N) patients (67% HIV-infected), was 52 (15) years, 126 (16) mmHg, and 30 (9) kg/m2, respectively. We observed that the HIV-infected (95% on HAART) females were younger [mean (SE) age; 47 (1.6) vs. 62 (1.3) years], had better controlled systolic blood pressure [132 (2.4) vs.139 (1.7) mmHg], lower proportion of diabetics (14% vs. 31%), and had a higher proportion of smokers (52% vs. 31%), compared to HIV-uninfected females (all p=   0.05). The 10-year primary risk for ASCVD in HIV-infected (age ≥ 40-79 years, 72% on HAART) compared to HIV-uninfected females was statistically different at baseline [mean (SE) risk score; 5.3 (1.5) % vs. 8.5 (1.3) %, p = 0.03)], but not at the last clinic visit [(5.6 (1.1) % vs. 7.5 (0.9) %, p= 0.11)]

Conclusions: From a minority cohort of a large metropolitan area, we report evidence of favorable CVD risk profile in HIV-infected AAF on HAART compared to their age-matched controls. However, the 10-year primary risk for ASCVD was similar over time between the two groups of females.
Better ways of learning
Authors: Peter Stride, Peter Scally
Journal: BMJ (2005)

Medical education teaches knowledge, skills, and attitudes. The knowledge is mainly about facts,and when these are correctly aligned they can be regarded as wisdom. The skills transferred to the students are usually manual skills, such as inserting an intravenous line or performing an electrocardiogram. The attitudes are to an extent a development of those that are already present in the undergraduate. One skill we believe is under-represented in medical courses is the skill of thinking. Is there a better way to teach students how to obtain information from the patient and combine that with knowledge that is known or accessible by the doctor? Also, is there a way to teach an optimal decision pathway in order to arrive at the conclusion of what to do for the best for the patient?
Diabetes Drug Warning
Authors: Rebecca Voelker
Journal: JAMA (2015)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 4: WISP-1 increases angiogenesis and VEGF-A expression in human oral squamous cell carcinomas
Authors: Ching-Wen Tsao, Chih-Hsin Tang, Jing-Yuan Chuang
Journal: Cancer Research (2014)

Abstract Oral squamous cell carcinomas (OSCC) is most common metastasis to cervical lymph nodes by angiogenesis. Wnt-1 induced secreted protein 1 (WISP-1) is a cysteine-rich protein that belongs to the CNN family (CTGF / CYR61 / NOV). However, the effects of WISP-1 on angiogenesis and Vascular endothelial growth factor- A (VEGF-A) expression in human OSCC are not clear. First, we found that the expression of WISP-1 in human OSCC tissues were higher than in normal oral tissues. We also demonstrated that WISP-1 enhanced angiogenesis and VEGF-A up-regulation in human OSCC. WISP-1 induced VEGF-A expressio and angiogenesis through αvβ3 integrin, FAK, c-Src, EGFR, and ERK pathway. Knockdown WISP-1 decreased VEGF-A expression and also abolished human OSCC condition medium-mediated angiogenesis in vitro as well as angiogenesis effects in the chick chorioallantoic membrane (CAM) and matrix gel plug nude mice model in vivo. In addition, in the xenograft tumor angiogenesis model, knockdown of WISP-1 significantly reduced tumor growth and tumor-associated angiogenesis. We characterized an important role for WISP-1 which regulates angiogenesis by increasing VEGF-A expression in human OSCC via the αvβ3 integrin, FAK, c-Src, EGFR, ERK, and HIF1-α signaling pathway. Citation Format: Ching-Wen Tsao, Chih-Hsin Tang, Jing-Yuan Chuang. WISP-1 increases angiogenesis and VEGF-A expression in human oral squamous cell carcinomas. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 4. doi:10.1158/1538-7445.AM2014-4